Product Description: Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis[1].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Finks SW, et al. Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant. Am J Med. 2017 May;130(5):e195-e197.